NEUROINFLAMMATION AND OXIDATIVE STRESS IN PARKINSON’S DISEASE PATHOGENESIS
DOI:
https://doi.org/10.55640/Keywords:
Parkinson’s disease, neuroinflammation, oxidative stress, microglia, reactive oxygen species, alpha-synuclein, mitochondrial dysfunction.Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta. Increasing evidence suggests that neuroinflammation and oxidative stress play central roles in the pathogenesis and progression of the disease. Chronic activation of microglia, elevated production of pro-inflammatory cytokines, mitochondrial dysfunction, and excessive reactive oxygen species (ROS) contribute to neuronal damage and alpha-synuclein aggregation. This article reviews the molecular mechanisms linking neuroinflammation and oxidative stress in Parkinson’s disease and discusses their potential as therapeutic targets. Understanding these interconnected pathways may provide new opportunities for disease-modifying strategies.Downloads
References
1.Dauer, W., & Przedborski, S. (2003). Parkinson’s disease: Mechanisms and models. Neuron, 39(6), 889–909.
2.Hirsch, E. C., & Hunot, S. (2009). Neuroinflammation in Parkinson’s disease: A target for neuroprotection? The Lancet Neurology, 8(4), 382–397.
3.Block, M. L., Zecca, L., & Hong, J. S. (2007). Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nature Reviews Neuroscience, 8(1), 57–69.
4.Jenner, P. (2003). Oxidative stress in Parkinson’s disease. Annals of Neurology, 53(S3), S26–S36.
5.Dias, V., Junn, E., & Mouradian, M. M. (2013). The role of oxidative stress in Parkinson’s disease. Journal of Parkinson’s Disease, 3(4), 461–491.
6.Gao, H. M., & Hong, J. S. (2008). Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Trends in Immunology, 29(8), 357–365.
7.Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell, 140(6), 918–934.
8.Schapira, A. H. V., Jenner, P., & Olanow, C. W. (1998). Mitochondrial dysfunction in Parkinson’s disease. Movement Disorders, 13(Suppl. 1), 58–62.
9.Barnham, K. J., Masters, C. L., & Bush, A. I. (2004). Neurodegenerative diseases and oxidative stress. Nature Reviews Drug Discovery, 3(3), 205–214.
10.Tansey, M. G., & Goldberg, M. S. (2010). Neuroinflammation in Parkinson’s disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiology of Disease, 37(3), 510–518.
11.Wang, Q., Liu, Y., & Zhou, J. (2015). Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Translational Neurodegeneration, 4(19), 1–9.
12.Henchcliffe, C., & Beal, M. F. (2008). Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nature Clinical Practice Neurology, 4(11), 600–609.
13.Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017). Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience, 18(2), 101–113.
14.Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A. E., & Lang, A. E. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India
